Collegium Pharmaceutical Inc (COLL)

Fixed asset turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	631,449	599,245	576,653	566,923	566,767	546,642	536,946	524,949	463,933	361,675	313,505	272,898	276,868	325,777	326,110	321,226	310,016	307,948	301,714	298,696
Property, plant and equipment	US$ in thousands	—	—	—	—	—	—	18,040	18,879	19,521	19,744	27,222	20,202	19,491	19,629	27,578	19,760	18,988	17,746	23,853	22,018
Fixed asset turnover		—	—	—	—	—	—	29.76	27.81	23.77	18.32	11.52	13.51	14.20	16.60	11.83	16.26	16.33	17.35	12.65	13.57

December 31, 2024 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $631,449K ÷ $—K
= —

The fixed asset turnover ratio for Collegium Pharmaceutical Inc has shown fluctuation over the past several quarters. The ratio was relatively stable in the range of 11 to 17 for most of 2020 and 2021, indicating that the company was generating sales efficiently from its fixed assets during this period.

However, there was a significant increase in the fixed asset turnover ratio towards the end of 2022, reaching 23.77 by December 31, 2022. This suggests that the company was able to generate a higher level of sales relative to its investment in fixed assets, indicating improved asset efficiency.

The trend continued to improve in 2023, with the fixed asset turnover ratio reaching 29.76 by June 30, 2023. This indicates that Collegium Pharmaceutical Inc was effectively utilizing its fixed assets to generate revenues during this period.

It is worth noting that data for the latter part of 2023 and beyond is not available, as indicated by the absence of figures for the fixed asset turnover ratio. This lack of data could be due to various reasons such as changes in reporting practices or a shift in business operations.

Overall, the trend in the fixed asset turnover ratio for Collegium Pharmaceutical Inc suggests that the company has been efficient in utilizing its fixed assets to generate revenues, with a notable improvement in asset turnover in late 2022 and early 2023.